AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease
This broad collaboration focuses on the US, China and all major markets excluding Japan, Europe, the Commonwealth of Independent States, ...
